Novo Nordisk's Valuation Trap: When the Cheaper Stock Isn't the Bargain

Novo Nordisk's CagriSema trails Lilly's Tirzepatid in trial, triggering stock slump and legal battle, while pipeline and manufacturing concerns mount.

The obesity-drug wars have produced an unusual spectacle: the company that invented the category now trades like a beaten-down value play, while its rival commands a growth premium that would have seemed unthinkable just a few years ago. Novo Nordisk's shares have fallen 7.9 percent since the start of the year and sit 26 percent below the January peak of 54.86 euros, a slide that accelerated after the company's CagriSema combination therapy failed to beat Eli Lilly's Tirzepatid in a head-to-head Phase 3 trial. The market's verdict was swift — a 2.5 percent drop to 40.56 euros on the day of the data release.

Yet the clinical setback, while real, tells only part of the story. The Danish pharmaceutical giant is simultaneously defending its franchise on multiple fronts: pricing pressure in the United States, a legal battle over marketing claims, questions about manufacturing quality at a recently acquired plant, and a pipeline that increasingly looks a step behind its Indiana-based rival.

The Trial That Changed the Narrative

The Redefine 4 study delivered a weight loss of 23.0 percent for CagriSema — a solid result by any historical standard, but one that fell short of the 25.5 percent achieved by Eli Lilly's Tirzepatid. More damaging than the absolute numbers was the miss on the trial's primary objective: demonstrating superiority over the competitor. That failure has dented the narrative that CagriSema would restore Novo Nordisk's clinical leadership in the obesity market.

The drug is not out of the race. The company expects a US Food and Drug Administration decision on CagriSema as an obesity treatment in the fourth quarter of 2026, and a missed superiority endpoint does not automatically translate into a regulatory rejection. But it strips the candidate of its claim to being the clear market leader, which matters for commercial momentum in a category where doctors and patients increasingly gravitate toward the most compelling efficacy data.

Adding to the operational noise, Scholar Rock disclosed that the fill-finish facility in Catalent Indiana — acquired by Novo Nordisk as part of its Catalent takeover — was removed from an approval filing for a different drug, Apitegromab, due to FDA concerns. The issue does not directly affect Novo Nordisk's own pipeline, but it raises questions about quality controls at the acquired manufacturing sites, a factor investors are watching closely.

A Legal Fight That Reveals the Stakes

The competitive tension spilled into the courtroom in late July, when Novo Nordisk filed a federal lawsuit against Eli Lilly alleging misleading advertising. The complaint centers on Lilly's marketing campaigns, which compared the maximum dose of Tirzepatid (marketed as Zepbound and Mounjaro) against lower doses of semaglutide — without mentioning the new 7.2-milligram injection dose of Wegovy that was approved in March 2026. The litigation has been running for over a month, but it underscores how fiercely both companies are competing for physician prescriptions in a market projected to exceed $150 billion by 2030.

The Numbers Behind the Divergence

The financial gap between the two companies has widened into a chasm. While Novo Nordisk reported second-quarter revenue of $12.1 billion, up 7 percent year over year, Eli Lilly posted a 48 percent revenue surge that sent its shares up 2.97 percent to $1,148.04 on the day both companies reported results on August 5. Novo Nordisk's shares managed a more modest 2.02 percent gain to $45.18.

The three-year compound annual growth rates tell the story more starkly. Eli Lilly has grown revenue at 31.2 percent annually versus Novo Nordisk's 18.4 percent. EBITDA growth shows an even wider gap: 35.8 percent for Lilly against 16.2 percent for the Dane. On a trailing twelve-month basis, Lilly's earnings per share have grown 49.3 percent while Novo Nordisk's adjusted EPS have contracted 6.6 percent. Looking ahead, analysts expect Lilly to grow another 28.5 percent over the next two years, while Novo Nordisk faces a projected decline of 4 to 12 percent.

The divergence is visible in market share as well. In the first half of 2026, roughly 60.1 percent of all new US prescriptions for injectable GLP-1 drugs went to Lilly's incretin family of Mounjaro and Zepbound. Novo Nordisk's counterattack relies on oral administration: the Wegovy pill reached 5 million prescriptions in the quarter, capturing 90 percent of the still-young oral obesity segment.

The Price of Playing Catch-Up

Novo Nordisk has chosen a defensive pricing strategy to protect its US market position. The company announced it would cut US list prices for Wegovy and Ozempic by up to 50 percent starting in 2027 to secure access to key reimbursement formularies. Adjusted US revenues fell 4 percent once one-time rebate provisions were stripped out — a decline the company attributes to a deliberate shift toward high-volume, lower-priced government and self-pay contracts.

Eli Lilly, by contrast, is spending its way to supply-chain dominance. More than $50 billion is earmarked for expanding US manufacturing capacity, an aggressive response to the shortages that plagued the category in earlier years. The company's research and development spending rose 28 percent, much of it directed at Retatrutide, a triple-acting hormone agonist. Phase 3 data this year showed weight loss of up to 22.6 percent — a level previously achievable only through bariatric surgery — and Lilly is targeting US approval in the first quarter of 2027.

Novo Nordisk's counterweight is CagriSema, a combination of semaglutide and cagrilintide, with internal data showing a solid 20.2 percent weight loss. The candidate trails Lilly's triple agonist, and the failed cardiovascular trial of Ziltivekimab has narrowed the company's diversification path beyond its core business.

Two Balance Sheets, Two Philosophies

The companies' financial structures reflect their strategic positions. Eli Lilly demonstrates extraordinary capital efficiency with a return on equity of 101.3 percent and a return on invested capital of 45.0 percent, supported by a debt-to-equity ratio of 1.39 — the leverage funding its global manufacturing build-out. Novo Nordisk runs a more conservative ship with a debt-to-equity ratio of 0.72 and a return on equity of 66.4 percent. The company generated $18.2 billion in operating cash flow but reinvested 74 percent of it back into production and research, leaving just $4.8 billion in free cash flow — a heavy reinvestment burden required to stay competitive against Lilly's manufacturing scale.

The valuation gap is equally pronounced. Novo Nordisk trades at 14.3 times expected earnings, an 11.2 EV/EBITDA multiple, and a price-to-book ratio of 12.8 — levels not seen since before Wegovy's original launch. Eli Lilly commands 32.6 times expected earnings and a 29.8 EV/EBITDA multiple. Yet the PEG ratio tells a more nuanced story: Lilly's 1.14 suggests the stock is actually cheaper relative to its growth rate, while Novo Nordisk's 2.15 indicates investors are paying a premium for a company whose earnings are expected to decline.

Signals of Confidence

Despite the headwinds, Novo Nordisk's management is signaling conviction. The company reaffirmed its full-year guidance, which projects adjusted revenue and profit growth of between 0 and minus 6 percent at constant exchange rates. CEO Mike Doustar told Reuters that the company still controls 90 percent of the oral GLP-1 market and characterized the competition with Lilly as a non-exclusive opportunity.

J.P. Morgan analyst Richard Wotser raised the price target to 275 Danish kroner from 250, citing stronger-than-expected international sales of Ozempic and Wegovy, while trimming expectations for the oral Wegovy version. The rating remains "Neutral" — not a buy signal, but hardly an alarm.

The company is also buying back shares aggressively. Between August 17 and 21, Novo Nordisk repurchased just over one million B-shares at prices between 293 and 299 kroner, part of an ongoing 11.2 billion kroner program that has accumulated roughly 15 million shares. Management buying into weakness is a classic confidence signal.

The Investor's Dilemma

The stock trades near its 200-day moving average with a relative strength index of 48.7 — neutral territory, neither oversold nor overextended. The risk profile differs meaningfully between the two companies: regulatory price caps carry a risk score of 20 points for Novo Nordisk versus 15 for Lilly, and the Danish company also bears greater exposure to pipeline setbacks and manufacturing disruptions.

The opportunity set tells a similar story. Lilly's potential Retatrutide market could reach $30 billion by 2028, while Novo Nordisk's CagriSema opportunity is estimated at $18 billion, with a possible 65 percent share of the oral market by 2027. In a composite scoring, Eli Lilly earns 86 out of 100 points, driven by explosive revenue growth, clinical leadership, and manufacturing scale. Novo Nordisk scores 68, with strengths in valuation, oral-market dominance, and a 3.9 percent dividend yield — but weaknesses in US pricing power, pipeline velocity, and recent revenue softness.

The choice ultimately comes down to temperament. Growth investors will find Eli Lilly's momentum irresistible, with the company on track for $100 billion in annual revenue. Contrarians, meanwhile, see in Novo Nordisk a classic recovery play — a franchise with real assets, a dominant oral position, and a valuation that already discounts considerable pessimism. The CagriSema setback is a genuine blow to the growth narrative, but it is not necessarily the turning point. The question is whether the pricing strategy and oral-market leadership can stabilize the business while the pipeline catches up — and whether investors have the patience to wait for the answer.